Thank you to everyone who was able to attend our May 2 Shareholder Update, which focused on Full Year 2023 financials, the acquisition of a new corporate campus announced April 16, and a discussion of our proposed path to a US listing. Watch full video with Q+A: https://bit.ly/3JUvJPn
BioHarvest Sciences
Biotechnology Research
Vancouver, British Columbia 2,055 followers
Leveraging the power of Botanical Synthesis technology to develop the next generation of science based Therapeutics
About us
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) is a public biotech company that has developed a patented Botanical Synthesis platform technology capable of growing the active and beneficial compounds in fruit & plants, at an industrial scale, without the need to grow the plant itself. BioHarvest has invested 16 years and >$75M to develop our Botanical Synthesis Technology, which produces unique and patentable botanical compositions which contain a “target optimized” combination of the phyto-medicinal compounds (with high solubility and bio-availability) found in the original plant. No other company has developed a commercially viable plant cell culture platform at the industrial scale of BioHarvest. BioHarvest is focused on leveraging this platform technology across the following business units: 1. Plant Cell Culture Development and Manufacturing: BioHarvest is leveraging its Botanical Synthesis technology to allow global pharmaceutical, cosmeceutical, and nutraceutical partners to develop proprietary botanical formulations with unmatched predictability and consistency, manufactured at industrial scale under exclusive partnerships. 2. Direct to Consumer/Direct to Doctor Nutraceuticals Business Anchored in Science: BioHarvest has built its own direct to consumer business of propriety botanical compositions. The first product, VINIA® was launched into the US in 2021 and has exceeded 50,000 users (>$20M USD Revenue). VINIA® contains multiple polyphenols, including Piceid Resveratrol, with an amount in each daily 400mg capsule that is equivalent to 1,000 grapes, resulting in a powerful nutraceutical that has been clinically proven (in a published double-blind placebo-controlled study), to significantly increase dilation of arteries. This increased dilation of arteries improves blood flow and the delivery of oxygen and nutrients to the body, tissue & organs. BioHarvest is the only company that produces red grape sourced Piceid resveratrol at an industrial scale
- Website
-
https://www.bioharvest.com
External link for BioHarvest Sciences
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Vancouver, British Columbia
- Type
- Public Company
- Founded
- 2018
Locations
-
Primary
625 Howe St.
Suite 1140
Vancouver, British Columbia V6C2T6, CA
Employees at BioHarvest Sciences
Updates
-
Corporate Update Webinar May 2, 2:30 pm EST. Join CEO Ilan Sobel and Chairman Zaki Rakib for a live discussion of recent milestones and of the FY 2023 Financials released April 30. Register: https://bit.ly/4aTejP8
-
"BioHarvest Sciences Reports Strong Financial Performance for 2023, Eyes Nasdaq Listing". CEO Ilan Sobel interviewed by Proactive Investors- watch interview: https://bit.ly/3y0xJDj
BioHarvest Sciences Reports Strong Financial Performance for 2023, Eyes Nasdaq Listing
https://www.youtube.com/
-
News Release--> BioHarvest Sciences Reports Fourth Quarter and Full Year 2023 Financial Results • Full Year 2023 Revenue Increased 2.3x to $12.7 Million USD • The Company expects Q1 2024 Revenue to be $5.2 million to $5.3 million and is providing Q2 2024 Revenue Guidance of $5.7-$6.0 million • Fourth quarter 2023 gross margins improved to 51%, as compared to 27% in the fourth quarter of 2022. Full year 2023 gross margins improved to 45%, as compared to 22% in 2022.
-
"BioHarvest Sciences secures new state of the art 80,0000 square foot manufacturing facility." CEO Ilan Sobel discusses new Corporate Campus and our plans to consolidate all aspects of research and production into one location. Watch Proactive interview: https://lnkd.in/gEXe-4uU
BioHarvest Sciences secures new state of the art 80,0000 square foot manufacturing facility
https://www.youtube.com/
-
April 16, 2024: BioHarvest Sciences Announces New Campus for Botanical Synthesis CDMO and Expansion of Manufacturing Capacity · 80,000 Square Foot (7,500 Square Meter) Property includes 12 GMP Clean Rooms, Laboratory and Office space, and can accommodate expanded 50 Ton Manufacturing facility · New Production Technologies Implemented at this Campus will serve to optimize the planned 150-ton USA manufacturing facility Read Full News Release: https://bit.ly/4432ljd
-
BioHarvest to present at the 14th LD Micro Small Cap Invitational, held in New York April 8+9, 2024. CEO Ilan Sobel's 25 minute presentation will be live streamed April 9 at 12pm ET. Watch live stream here: https://bit.ly/3vIvS5e
-
"Our Products division has allowed us to monetize the power of our Botanical Synthesis process technology.." CEO Ilan Sobel discusses our new CDMO division, which adds a Services Business Unit to complement the Direct-to-Consumer revenue engine. Watch the complete March 13 Corporate Update here: https://bit.ly/4aj6Rg8
BioHarvest CDMO Launch -Shareholder Update
https://www.youtube.com/
-
New Podcast published--> 'Wall Street Resource' host Jeff Kone hosts CEO Ilan Sobel to discuss our Botanical Synthesis technology and the new BioHarvest CDMO Business Unit. Listen to podcast here: https://lnkd.in/dvAhfke
-
News Release --> BioHarvest Sciences Appoints Anna Tenstam as VP of Business Development, Cosmeceuticals and Injectables. "Experienced Life Sciences Executive to Support Cosmeceuticals and Injectables Growth for New CDMO Business Unit". Read full release: https://lnkd.in/gTK8vwdK Welcome to the BioHarvest team, Anna!